Prior report showed that intertumoral angiogenic heterogeneity was observed in HNSCC PDX models and the therapeutic response anti-VEGF therapy was dependent on their angiogenic heterogeneity [44]. The gene discussed is VEGFA; the disease is head and neck squamous cell carcinoma.